GW Pharmaceuticals PLC- ADR operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares GW Pharmaceuticals PLC- ADR with three other
companies in this sector in the United States:
Luna Innovations Incorporated
sales of $44.02 million
of which 69%
was New Drug Development), and
Exact Sciences Corporation
of which 100%
was License fees).
GW Pharmaceuticals PLC- ADR reported sales of $43.99 million
September of 2015.
decrease of 11.8%
versus 2014, when the company's sales were $49.89 million.
The sales level in 2015 was fairly close to the level five years ago: in 2010, GW Pharmaceuticals PLC- ADR had sales
of $47.80 million.
Contributing to the drop in overall sales was the 25.5% decline
in Pipeline R&d, from $1.11 million to $824,675.75 .
There were also decreases in sales in
Sativex R&d (down 12.4% to $34.34 million)
Commercial (down 7.7% to $8.83 million)